Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2B | P29275 | 10/20 | 0.43 |
| ▸ | ADORA2A | P29274 | 9/20 | 0.43 |
| ▸ | ADORA1 | P30542 | 9/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.43 |
| ▸ | ADORA3 | P0DMS8 | 7/20 | 0.41 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.39 |
| ▸ | CREBBP | Q92793 | 3/20 | 0.39 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.37 |
| ▸ | BRD4 | O60885 | 1/20 | 0.36 |
| ▸ | KDM1A | O60341 | 1/20 | 0.36 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.36 |
| ▸ | SCD | O00767 | 1/20 | 0.35 |
| ▸ | SCD5 | Q86SK9 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29081773 | 1.00 | ADORA2B (0.43) | ADORA2BADORA2AADORA1L3MBTL1ADORA3 | |
| SCHEMBL29081774 | 1.00 | ADORA2B (0.43) | ADORA2BADORA2AADORA1L3MBTL1ADORA3 | |
| SCHEMBL29324174 | 0.85 | L3MBTL1 (0.44) | ADORA2BADORA2AADORA1L3MBTL1ADORA3 | |
| SCHEMBL24364183 | 0.77 | CYP2C19 (0.48) | ADORA2AADORA1L3MBTL1PRMT5CREBBP | |
| SCHEMBL24365560 | 0.77 | LMNA (0.40) | — | |
| SCHEMBL21193640 | 0.72 | L3MBTL1 (0.43) | L3MBTL1PRMT5CREBBPALKBRD4 | |
| SCHEMBL21192852 | 0.69 | L3MBTL1 (0.43) | L3MBTL1PRMT5CREBBPALKBRD4 | |
| SCHEMBL29324288 | 0.69 | L3MBTL1 (0.50) | ADORA2BADORA2AADORA1L3MBTL1ADORA3 | |
| SCHEMBL16545298 | 0.68 | L3MBTL1 (0.48) | ADORA2AADORA1L3MBTL1PRMT5CREBBP | |
| SCHEMBL24366545 | 0.68 | L3MBTL1 (0.51) | ADORA2BADORA2AADORA1L3MBTL1ADORA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240228478-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. | 2024-07-11 | — | — | US | disclosed |
| US-20240228478-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. | 2024-07-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240228478-A1 | COMPOUNDS AND METHODS OF USE | F12, C1R, ABCG2 | ADORA2B 84/4885ADORA2A 275/4885ADORA1 58/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.